West Pharmaceutical Services, Inc. reported its third-quarter 2026 financial results, announcing an increase to its full-year net sales and adjusted diluted earnings per share (EPS) guidance. For the three months ended September 30, 2026, the company reported net sales of $874.5 million, an 8.7% increase compared to the prior year period. On an organic basis, sales grew by 11.9%. Diluted EPS for the quarter was $3.02, representing a 57.3% increase year-over-year. Adjusted diluted EPS was $2.66, up 35.7%.
The company’s results were driven by its Proprietary Products segment, which reported net sales of $728.8 million, a 12.6% increase. Within this segment, High-Value Product (HVP) Components net sales reached $466.7 million, a 19.7% increase, accounting for 53% of total company net sales. Conversely, the West Vantage segment saw net sales of $145.7 million, a 7.3% decrease.
West Pharmaceutical Services also updated its capital expenditure guidance for the full year 2026 to a range of $215 million to $220 million, down from the previous estimate of $250 million to $275 million. The company repurchased $231 million of its common stock during the third quarter, bringing year-to-date buybacks to $685 million. Additionally, the company announced a fourth-quarter dividend of $0.26 per share, an 18% increase over the prior quarter.
Regarding full-year outlook, the company raised its net sales guidance to a range of $3.41 billion to $3.42 billion, up from the previous range of $3.345 billion to $3.380 billion. Organic net sales growth guidance was increased to a range of 11.3% to 11.6%. Adjusted diluted EPS guidance for the full year was raised to a range of $9.38 to $9.48, up from the prior range of $8.85 to $9.05.
